




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ABLE-0021  
Inventors: Secombes et al.  
Serial No.: 10/088,780  
Filing Date: July 22, 2002  
Examiner: Kelly, Robert M.  
Customer No.: 26259  
Group Art Unit: 1632  
Confirmation No.: 9521  
Title: Monoclonal Antibody 3F1H10  
Neutralising VHSV

"Express Mail" Label No. EV540196193US  
Date of Deposit September 7, 2004

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Mail Stop Fee Amendment, Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450.

By   
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with  
37 C.F.R. §§1.97-1.98, information relating to the above-  
identified application is hereby disclosed. Inclusion of  
information in this statement is not to be construed as an  
admission that this information is material as that term is  
defined in 37 C.F.R. §1.56(b).

09/09/2004 CCHAU1 00000084 501619 10088780

02 FC:1806 180.00 DA

( ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

(XX) The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification

in Accordance with §1.97(e); Petition Requesting  
Consideration of the Information Disclosure Statement;  
and the fee of \$130.00 as set forth in §1.17(i)(1).


- ( ) Copies of each of the references listed on the  
attached Form PTO-1449 (modified) are enclosed  
herewith.
- ( ) In accordance with §1.98(d), copies of some or all of  
the references listed on the attached Form PTO-1449  
(modified) are not enclosed herewith because they were  
previously submitted to the U.S. Patent and Trademark  
Office in prior application Serial No. @@, filed @@  
for which a claim for priority under 35 U.S.C. §120  
has been made in the instant application.

Please charge any deficiency or credit any overpayment  
to Deposit Account No. 50-1619. This form is submitted in  
duplicate.

- ( ) The relevance of the listed references in a foreign  
language is as stated in the specification at pages  
@@.

(XX) All listed references are in the English language.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Kathleen A. Tyrrell', written over the printed name.

Kathleen A. Tyrrell  
Registration No. 38,350

Date: September 7, 2004

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>ABLE-0021</b>	<b>Serial No.</b> <b>10/088,780</b>
<b>List of Patents and Publications Cited by Applicant (Use several sheets if necessary)</b>		<b>Applicant</b> <b>Urbaniak et al.</b>	
		<b>Filing Date</b> <b>July 22, 2002</b>	<b>Group</b> <b>1632</b>
<b>U.S. Department of Commerce</b>			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AE	Prasad et al., "In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response", <i>Cancer Gene Therapy</i> , Jul-Aug 1997 4:253-259	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	